Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i>
<i>Staphylococcus epidermidis</i> is frequently implicated in medical device-related infections. As a result of this, novel approaches for control of this opportunistic pathogen are required. We examined the ability of the natural peptide nisin A, produced by <i>Lactococcus lactis&...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/9/6/305 |
| _version_ | 1827715503888531456 |
|---|---|
| author | Ellen Twomey Colin Hill Des Field Maire Begley |
| author_facet | Ellen Twomey Colin Hill Des Field Maire Begley |
| author_sort | Ellen Twomey |
| collection | DOAJ |
| description | <i>Staphylococcus epidermidis</i> is frequently implicated in medical device-related infections. As a result of this, novel approaches for control of this opportunistic pathogen are required. We examined the ability of the natural peptide nisin A, produced by <i>Lactococcus lactis</i>, to inhibit <i>S. epidermidis.</i> In addition, a bank of 29 rationally selected bioengineered <i>L. lactis</i> strains were examined with the aim of identifying a nisin derivative with enhanced antimicrobial activity. Agar-based deferred antagonism assays revealed that wild type nisin A inhibited all 18 <i>S. epidermidis</i> strains tested. Larger zones of inhibition than those obtained from the nisin A producing <i>L. lactis</i> strain were observed for each derivative producer against at least one <i>S. epidermidis</i> strain tested. Six derivative producing strains, (VGA, VGT, SGK, M21A, M17Q, AAA), gave larger zones against all 18 strains compared to the wildtype producing strain. The enhanced bioactivity of M17Q was confirmed using well diffusion, minimum inhibitory concentration (MIC) and a broth-based survival assays. Biofilm assays were performed with plastic microtiter plates and medical device substrates (stainless-steel coupons and three catheter materials). The presence of nisin A significantly reduce the amount of biofilm formed on all surfaces. M17Q was significantly better at reducing biofilm production than nisin A on plastic and stainless-steel. Finally, M17Q was significantly better than nisin A at reducing bacterial numbers in a simulated wound fluid. The findings of this study suggest that nisin and bioengineered derivatives warrant further investigation as potential strategies for the control of <i>S. epidermidis.</i> |
| first_indexed | 2024-03-10T19:19:55Z |
| format | Article |
| id | doaj.art-70efc546522b427fb300db6d6ea47640 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T19:19:55Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-70efc546522b427fb300db6d6ea476402023-11-20T03:02:19ZengMDPI AGAntibiotics2079-63822020-06-019630510.3390/antibiotics9060305Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i>Ellen Twomey0Colin Hill1Des Field2Maire Begley3Department of Biological Sciences, Cork Institute of Technology, T12 P928 Cork, IrelandSchool of Microbiology, University College Cork, T12 YN60 Cork, IrelandSchool of Microbiology, University College Cork, T12 YN60 Cork, IrelandDepartment of Biological Sciences, Cork Institute of Technology, T12 P928 Cork, Ireland<i>Staphylococcus epidermidis</i> is frequently implicated in medical device-related infections. As a result of this, novel approaches for control of this opportunistic pathogen are required. We examined the ability of the natural peptide nisin A, produced by <i>Lactococcus lactis</i>, to inhibit <i>S. epidermidis.</i> In addition, a bank of 29 rationally selected bioengineered <i>L. lactis</i> strains were examined with the aim of identifying a nisin derivative with enhanced antimicrobial activity. Agar-based deferred antagonism assays revealed that wild type nisin A inhibited all 18 <i>S. epidermidis</i> strains tested. Larger zones of inhibition than those obtained from the nisin A producing <i>L. lactis</i> strain were observed for each derivative producer against at least one <i>S. epidermidis</i> strain tested. Six derivative producing strains, (VGA, VGT, SGK, M21A, M17Q, AAA), gave larger zones against all 18 strains compared to the wildtype producing strain. The enhanced bioactivity of M17Q was confirmed using well diffusion, minimum inhibitory concentration (MIC) and a broth-based survival assays. Biofilm assays were performed with plastic microtiter plates and medical device substrates (stainless-steel coupons and three catheter materials). The presence of nisin A significantly reduce the amount of biofilm formed on all surfaces. M17Q was significantly better at reducing biofilm production than nisin A on plastic and stainless-steel. Finally, M17Q was significantly better than nisin A at reducing bacterial numbers in a simulated wound fluid. The findings of this study suggest that nisin and bioengineered derivatives warrant further investigation as potential strategies for the control of <i>S. epidermidis.</i>https://www.mdpi.com/2079-6382/9/6/305bacteriocinantibacterial peptidebioengineered peptidenisin<i>Staphylococcus epidermidis</i>medical device related infections |
| spellingShingle | Ellen Twomey Colin Hill Des Field Maire Begley Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i> Antibiotics bacteriocin antibacterial peptide bioengineered peptide nisin <i>Staphylococcus epidermidis</i> medical device related infections |
| title | Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i> |
| title_full | Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i> |
| title_fullStr | Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i> |
| title_full_unstemmed | Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i> |
| title_short | Bioengineered Nisin Derivative M17Q Has Enhanced Activity against <i>Staphylococcus epidermidis</i> |
| title_sort | bioengineered nisin derivative m17q has enhanced activity against i staphylococcus epidermidis i |
| topic | bacteriocin antibacterial peptide bioengineered peptide nisin <i>Staphylococcus epidermidis</i> medical device related infections |
| url | https://www.mdpi.com/2079-6382/9/6/305 |
| work_keys_str_mv | AT ellentwomey bioengineerednisinderivativem17qhasenhancedactivityagainstistaphylococcusepidermidisi AT colinhill bioengineerednisinderivativem17qhasenhancedactivityagainstistaphylococcusepidermidisi AT desfield bioengineerednisinderivativem17qhasenhancedactivityagainstistaphylococcusepidermidisi AT mairebegley bioengineerednisinderivativem17qhasenhancedactivityagainstistaphylococcusepidermidisi |